108 related articles for article (PubMed ID: 16803841)
1. Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes.
Chou WC; Huang SF; Yeh KY; Wang HM; Liu MY; Hsieh JJ; Cheung YC; Chang JW
Jpn J Clin Oncol; 2006 Aug; 36(8):523-6. PubMed ID: 16803841
[TBL] [Abstract][Full Text] [Related]
2. A new mechanism for primary resistance to gefitinib in lung adenocarcinoma: the role of a novel G796A mutation in exon 20 of EGFR.
Uramoto H; Uchiumi T; Izumi H; Kohno K; Oyama T; Sugio K; Yasumoto K
Anticancer Res; 2007; 27(4B):2297-303. PubMed ID: 17695517
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
[TBL] [Abstract][Full Text] [Related]
4. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.
Wu SG; Chang YL; Hsu YC; Wu JY; Yang CH; Yu CJ; Tsai MF; Shih JY; Yang PC
Oncologist; 2008 Dec; 13(12):1276-84. PubMed ID: 19060236
[TBL] [Abstract][Full Text] [Related]
5. Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.
Yang TY; Tsai CR; Chen KC; Hsu KH; Lee HM; Chang GC
J Clin Oncol; 2011 Jun; 29(16):e468-9. PubMed ID: 21422421
[No Abstract] [Full Text] [Related]
6. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
Balak MN; Gong Y; Riely GJ; Somwar R; Li AR; Zakowski MF; Chiang A; Yang G; Ouerfelli O; Kris MG; Ladanyi M; Miller VA; Pao W
Clin Cancer Res; 2006 Nov; 12(21):6494-501. PubMed ID: 17085664
[TBL] [Abstract][Full Text] [Related]
7. Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome.
Ushiki A; Koizumi T; Kobayashi N; Kanda S; Yasuo M; Yamamoto H; Kubo K; Aoyagi D; Nakayama J
Jpn J Clin Oncol; 2009 Apr; 39(4):267-70. PubMed ID: 19155283
[TBL] [Abstract][Full Text] [Related]
8. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.
Oh IJ; Ban HJ; Kim KS; Kim YC
Lung Cancer; 2012 Jul; 77(1):121-7. PubMed ID: 22333554
[TBL] [Abstract][Full Text] [Related]
9. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
Chang JW; Liu HP; Hsieh MH; Fang YF; Hsieh MS; Hsieh JJ; Chiu YT; Tsai HY; Chen YH; Chen YT; Hsu HY; Chen YT; Tsai SF; Chen YR; Hsi BL; Huang SF
Lung Cancer; 2008 Sep; 61(3):328-39. PubMed ID: 18304690
[TBL] [Abstract][Full Text] [Related]
10. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
Shih JY; Gow CH; Yang PC
N Engl J Med; 2005 Jul; 353(2):207-8. PubMed ID: 16014893
[No Abstract] [Full Text] [Related]
11. High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma.
Moiseyenko VM; Procenko SA; Levchenko EV; Barchuk AS; Moiseyenko FV; Iyevleva AG; Mitiushkina NV; Togo AV; Semionov II; Ivantsov AO; Matsko DE; Imyanitov EN
Onkologie; 2010; 33(5):231-8. PubMed ID: 20502057
[TBL] [Abstract][Full Text] [Related]
12. Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung.
Kozuki T; Hisamoto A; Tabata M; Takigawa N; Kiura K; Segawa Y; Nakata M; Mandai K; Eguchi K; Ueoka H; Tanimoto M
Lung Cancer; 2007 Oct; 58(1):30-5. PubMed ID: 17561305
[TBL] [Abstract][Full Text] [Related]
13. Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L.
Asahina H; Yamazaki K; Kinoshita I; Yokouchi H; Dosaka-Akita H; Nishimura M
Lung Cancer; 2006 Dec; 54(3):419-22. PubMed ID: 17045698
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
Choi YJ; Rho JK; Jeon BS; Choi SJ; Park SC; Lee SS; Kim HR; Kim CH; Lee JC
Cancer Chemother Pharmacol; 2010 Jul; 66(2):381-8. PubMed ID: 19921194
[TBL] [Abstract][Full Text] [Related]
15. Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations.
Chung KP; Shih JY; Yu CJ
J Clin Oncol; 2010 Dec; 28(34):e701-3. PubMed ID: 20823418
[No Abstract] [Full Text] [Related]
16. Diffuse micronodular pulmonary metastasis of lung adenocarcinoma predicts gefitinib response in association with epidermal growth factor receptor mutations.
Kobayashi M; Takeuchi T; Bandobashi K; Uemura Y; Ogawa Y; Ohtsuki Y; Taguchi H
Anticancer Res; 2006; 26(2B):1621-6. PubMed ID: 16619582
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma.
Hijiya N; Miyawaki M; Kawahara K; Akamine S; Tsuji K; Kadota J; Akizuki S; Uchida T; Matsuura K; Tsukamoto Y; Moriyama M
Hum Pathol; 2008 Mar; 39(3):316-23. PubMed ID: 18261621
[TBL] [Abstract][Full Text] [Related]
18. Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.
Alam N; Gustafson KS; Ladanyi M; Zakowski MF; Kapoor A; Truskinovsky AM; Dudek AZ
Clin Lung Cancer; 2010 Sep; 11(5):E1-4. PubMed ID: 20837450
[TBL] [Abstract][Full Text] [Related]
19. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
Kondo M; Yokoyama T; Fukui T; Yoshioka H; Yokoi K; Nagasaka T; Imaizumi K; Kume H; Hasegawa Y; Shimokata K; Sekido Y
Lung Cancer; 2005 Dec; 50(3):385-91. PubMed ID: 16140420
[TBL] [Abstract][Full Text] [Related]
20. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
Kim DW; Lee SH; Lee JS; Lee MA; Kang JH; Kim SY; Shin SW; Kim HK; Heo DS
Lung Cancer; 2011 Jan; 71(1):65-9. PubMed ID: 20430469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]